Navigation Links
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
Date:4/26/2011

INDIANAPOLIS and MINNEAPOLIS, April 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) today announced they have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new  medicine to the brain using an implantable drug delivery system. The goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lilly's biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system technology.

"We believe we have biosynthetically engineered this GDNF variant to overcome technical hurdles of previous research in this area and are hopeful that early testing of our biologic with Medtronic's device will provide the necessary data to safely advance into human studies," said Michael L. Hutton, Ph.D., chief scientific officer of the neurodegeneration team at Lilly. "By collaborating with Medtronic from the earliest phase of research, we are maximizing the potential for this therapy's efficient and effective development."

Parkinson's disease is a neurodegenerative condition caused by progressive loss of neurons in the brain that produce dopamine, a chemical messenger responsible for transmitting signals that allow for coordination of movement. As a result, patients with Parkinson's disease experience balance problems, tremors and muscular stiffness, among other symptoms which worsen over time.  It is estimated that 7 million to 10 million people worldwide are living with Parkinson's disease(i) and there is no cure. Around the world, April is Parkinson's Awareness Month.

Applying its expertise in biotechnology, Lilly has designed its GDNF variant with the intent to achieve increased distribution in targeted brain regions. Medtronic has developed a drug pump and specially designed catheter to enable precise delivery of the GDNF variant into a targeted area of the brain consistently over time. This combination of a novel GDNF variant, paired with an optimized delivery system, has the potential to impact the neurodegeneration that leads to worsening symptoms and progression of Parkinson's disease.  

"Our collaboration with Lilly is bringing together the expertise of both companies to develop a new approach to the treatment of Parkinson's disease," said Steve Oesterle, M.D., senior vice president of Medicine and Technology at Medtronic.  "One of the most significant challenges in delivering a biologic treatment for neurodegenerative diseases is crossing the blood brain barrier.  We have extensive experience in targeted drug delivery and technology that allow delivery of therapeutic agents directly to the brain."

"While a potential treatment approach resulting from this research is many years away, we are heartened by Lilly and Medtronic's commitment to develop a neurotrophic-based therapy for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation for Parkinson's Research. "Our foundation has funded separate, ongoing work in neurotrophic factors for years, and we continue to believe in their promise to lead to a critically needed disease-modifying treatment for Parkinson's."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

P-LLY

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the managements of Lilly and Medtronic, and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. The companies undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause their results to differ materially from those described in the forward-looking statements can be found in their most recent Forms 10-K and 10-Q, and each company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

(i)  The Parkinson's Disease Foundation, http://www.pdf.org/en/parkinson_statistics. Accessed 3/18/2011.

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo:  http://photos.prnewswire.com/prnh/20080519/DE19417LOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):